Tumors of the central nervous system are the second most common malignancy in children. In particular, diffuse intrinsic pontine gliomas (DIPGs) are aggressive tumors with poor prognosis and account for 10% to 25% of pediatric brain tumors. The majority of DIPGs are astrocytic, infiltrative, and localized to the pons. Studies have shown median survival times of less than a year, with 90% of children dying within 2 years. We built multitissue arrays with 24 postmortem DIPG samples and analyzed the morphology and expression of several proteins (p53, EGFR, GFAP, MIB1, BMI1, b-catenin, p16, Nanog, Nestin, OCT4, OLIG2, SOX2) with the goal of identifying potential treatment targets and improving our understanding of the biology of these tumors. The majority of DIPGs were high-grade gliomas (22), with 18 cases having features of glioblastoma (World Health Organization [WHO] grade IV) and 4 cases with high-grade features consistent with anaplastic astrocytoma (WHO grade III). One case was low grade (WHO grade II), and 1 case showed intermediate features between a grade II and grade III glioma (low mitotic rate but increased cellularity and cell atypia), being difficult to grade precisely. The majority of the tumors were positive for GFAP (24/24), MIB1 (23/24), OLIG2 (22/24), p16 (20/24), p53 (20/24), SOX2 (19/24), EGFR (16/24), and BMI1 (9/24). Our results suggest that dysregulation of EGFR and p53 may play an important role in the development of DIPGs. The majority of DIPGs express stem cell markers such as SOX2 and OLIG2, consistent with a role for tumor stem cells in the origin and maintenance of these tumors. Targeted therapies against these proteins could be beneficial in treatment.
P ediatric tumors of the central nervous system are the second most common malignancy in children. 1 Brainstem gliomas account for 10% to 25% of brain neoplasms in children, 2, 3 and the most common subtype, diffuse intrinsic pontine glioma (DIPG), is an aggressive tumor with poor prognosis. These tumors are of astrocytic origin with an infiltrative pattern and involving the pons. The diagnosis of DIPG is based on a characteristic clinical and radiographic presentation on magnetic resonance imaging, although distinction from primitive neuroectodermal tumors on imaging studies alone may be difficult. There has been debate regarding the value of performing diagnostic biopsies in cases with imaging findings suggestive of DIPGs. [4] [5] [6] Currently, biopsies are not performed in most cases, given the possibility of adverse outcomes associated with the procedure and the limited influence of the information on patient management.
Surgical removal of DIPGs is almost always not possible because of their location and relation to vital anatomic structures. Therefore, treatment strategies have traditionally been limited to radiotherapy and chemotherapy with very poor effectiveness. Most studies have shown median survival time of less than a year from diagnosis, and 90% of children die within 2 years. 3 A number of chemotherapeutic agents and radiotherapy strategies have been tried in the past with little success. 3, 7 As diagnostic biopsy or surgical excision is typically not performed, the tumor tissue available for research studies is extremely scarce. This has limited our understanding of the biology of these tumors, making it difficult to rationally select treatment strategies for clinical trials.
Recent literature suggests an important role for tumor stem cells in the development, progression, and treatment resistance of brain gliomas. A number of genomic studies have identified various genetic abnormalities, but it is not clear how these mutations alter protein expression in DIPGs. 8, 9 Regulatory factors (OCT4, SOX2, and Nanog) involved in maintaining pluripotency and self-renewal in embryonic stem cells have been shown to be expressed in adult gliomas. 10, 11 Monje and colleagues reported the identification of a pontine precursorlike cell (PPC) population in normal human ventral pons with temporal expression coinciding with the incidence of DIPGs. This pontine precursor-like cell population showed expression of Nestin and OLIG2 and was proposed as a potential cell of origin for DIPGs. However, there is limited information regarding the expression of these proteins in DIPGs. In addition, information on the histology and cell biology of DIPGs is limited.
We evaluated histology and protein expression in a set of DIPGs in order to improve our understanding of the biology of these tumors and to identify potential therapeutic targets. We built multitissue arrays with 24 DIPG samples obtained postmortem and analyzed the morphology of the tumors and the expression of proteins related to stem cell phenotype (Nanog, Nestin, OCT4, OLIG2, SOX2, BMI1, b-catenin), differentiation (GFAP, synaptophysin), proliferation (MIB1), and molecular factors altered in gliomas (p53, EGFR, p16, mutant IDH1).
METHODS

Tissue Samples
Postmortem brain tissues from 24 cases of pediatric DIPG were included. Some were from autopsies performed at the National Institutes of Health, whereas others were outside material submitted to our institution with limited clinical information. The study included 11 boys and 9 girls and 4 samples in which the sex of the patient was not known. The age at the time of death ranged from 3 to 15 years, with a median age of 7. Patient demographics are summarized in Table 1 . Two multitissue arrays including samples from 24 cases were constructed as previously described. 12 
Immunohistochemical Studies
Fourteen proteins of interest were selected on the basis of published literature. Antibodies for these proteins were procured and optimized for immunohistochemistry (IHC). Table 2 summarizes the product information and dilution factors for all the antibodies used in the study. IHC staining for Nanog, OCT4, and SOX2 was performed manually using Dako EnVision+Mouse in vitro detection systems (Dako, Glostrup, Denmark), whereas that for GFAP, p53, IDH1, MIB1, p16, and synaptophysin was performed using a Ventana Benchmark autostainer (Ventana Medical Systems, Tucson, AZ) and for OLIG2, BMI, Nestin, and b-catenin using a Leica BOND-MAX autostainer (Leica Microsystems, Wetzlar, Germany). All protocols were performed according to the manufacturer's specifications. Application of the primary antibody was preceded by avidin-biotin block (Dako). Epitope retrieval modality was selected by comparing the results of retrieval on a multitissue control block containing 30 different tissues. Staining results were interpreted and reported on the basis of the percentage of positive cells in the tissue sample. For MIB1, the percentage of reactive nuclei was calculated by 2 pathologists (M.M.Q. and L.Y.B.) as the estimated number of positive cells divided by the estimated number of total cells multiplied by 100. Mitoses were evaluated in 50 HPF or until all the tissue in the array was examined. IHC stains were 
Mitoses were evaluated in 50 HPF or until all the tissue in the array was examined. VP indicates vascular proliferation; Â , observed; -, not observed. scored using a scale of 1 to 5, where 1 = < 5%, 2 = 5% to 25%, 3 = 25% to 50%, 4 = 50% to 75%, 5 = 75% to 100%.
RESULTS
Morphologic Features
The majority of the cases analyzed were high-grade astrocytomas (22 cases) with 18 cases having diagnostic features of glioblastoma, World Health Organization (WHO) grade IV, and 4 cases with high-grade features (mitosis, increased cellularity, high proliferation rate) consistent with anaplastic astrocytoma, WHO grade III. One case was low grade (WHO grade II), and 1 case showed intermediate features between a grade II and grade III astrocytoma (low mitotic rate but increased cellularity and cell atypia), being difficult to grade precisely. All lesions were localized to the brainstem, with 1 lesion extending into the cerebellum and another lesion involving the thalamus.
Although all the samples demonstrated increased cellularity relative to normal brain, the degree of cellularity varied among cases, with 5 cases showing lower cellularity and 19 cases being highly cellular. Four of the 5 cases with low cellularity showed a low proliferative index (MIB1-labeling index <5%). The number of mitoses was also varied ranging from 0 to 26 in the sample represented on the tissue array ( Fig. 1A ). For the most part, there was a directly proportional relationship between the number of mitoses seen and the percentage of MIB1 labeling. Features of glioblastoma, such as pseudopalisading necrosis (13/24, 54%) and glomeruloid vascular proliferation (16/24, 66%), were a common finding ( Fig. 1B) . Microcalcifications were present in 3 of the cases (Fig. 1C ), 2 of which also showed a minor component of gemistocytes (< 20% of tumor cells). The tumor cells were mostly fibrillary with 2 cases showing giant cells ( Fig. 1D ), whereas 2 other lesions contained pilocytic and Am J Surg Pathol Volume 37, Number 9, September 2013 Characterization of DIPG myxoid microcystic features in some areas, respectively. Rosenthal fibers, eosinophilic granular bodies, or true angiocentric arrangement of tumor cells were not present, making a diagnosis of pilocytic astrocytoma or pilomyxoid astrocytoma unlikely. The majority of the lesions showed a clearly infiltrative pattern with tumor cells aligning along white matter tracts. For selected cases, whole-mount sections with a larger area of tissue represented in the tissue block were prepared. These sections revealed a significant degree of intratumor morphologic diversity with regard to cellularity and degree of pleomorphism.
IHC Markers
Several IHC staining analyses were performed in the tissue array (Table 3 ). In all cases, the tumor cells were positive for GFAP ( Fig. 2A) and negative for synaptophysin. Proliferation index assessed by MIB1 labeling (Fig. 2B ) ranged from <1% to 40% with a mean of 12%. Eleven cases showed MIB1 staining of >10%, and, with the exception of 1 case (#22), the cases with high MIB1 labeling showed a significant number of mitoses. A prior study by Yoshimura et al 13 also reported high MIB1 labeling in a series of diffuse brainstem gliomas.
Selected Molecular Pathways
In an attempt to better understand the biology and molecular origin of these tumors, as well as to identify potential therapeutic targets, we analyzed the expression of several glioma-associated proteins in the 24 DIPGs. The tyrosine kinase receptor EGFR is frequently amplified and/or overexpressed in malignant gliomas, 14, 15 and 16 of the 24 (66%) DIPG cases showed variable EGFR membranous expression ( Fig. 2C ). EGFR expression could be divided into cases in which <5% of cells are positive (4 cases) or >30% of cells are positive (10 cases). Two cases showed intermediate positivity (between 5% and 29%), and 8 cases were negative. Twenty of 24 (83%) cases showed increased staining for p53 ( Fig. 2D ), whereas p16 protein was expressed in 21/23 (91%) (Fig. 3A) . Mutant IDH1 immunostains were negative in all cases (Fig. 3B) .
Tumor stem cells are proposed to play a role in tumorigenesis, recurrence, and resistance to treatment in brain gliomas, a subject that has received significant attention in the recent literature. We evaluated the expression of genes involved in stem cell regulation including Nestin, Nanog, SOX2, and OCT3/4 in the 24 DIPGs using IHC in the tissue microarray (TMA). Nestin was expressed in 5/24 (21%) cases (Fig. 3C ), SOX2 in 19/ 24 (79%) cases (Fig. 3D) , and OCT3/4 in 3/24 (12%) cases (Fig. 4A ). OLIG2 was positive in 22/24 (92%) cases (Fig. 4B) . In contrast, all cases were negative for Nanog. We found expression of BMI1 in 6/24 (25%) DIPGs (Fig. 4C ). Nuclear translocation of b-catenin has been associated with Wnt activation and cancer stem cell phenotype; however, although it was expressed in 7/24 (29%) cases, all these cases showed only a submembranous/cytoplasmic pattern (Fig. 4D ). Nuclear staining (translocation) was not identified.
DISCUSSION
The majority of children with DIPG present with a characteristic set of symptoms and classic radiographic findings. Despite this, our study shows that these tumors vary histologically and have a heterogenous pattern of expression for various proteins. The value of performing diagnostic biopsies for cases of suspected DIPGs continues to be a matter of debate. Interpatient and intrapatient morphologic variability is an important finding that must be kept in mind at the time of evaluating biopsy specimens. In addition, it is important to distinguish diffuse pontine gliomas from other brainstem gliomas such as pilocytic astrocytomas, which have a much better prognosis. OLIG2 is a transcription factor involved in development of oligodendrocytes and has been proposed to play an important role in the development of malignant gliomas from neural stem cells. In a study by Otero et al 16 examining 90 pediatric brain tumors, all astrocytic tumors showed diffuse OLIG2 expression with glioblastomas and pilocytic astrocytomas showing the highest expression levels. Recent studies have shown that the majority of DIPGs contain the H3.3 K27M mutation and express OLIG2, whereas pediatric supratentorial glioblastomas frequently have the H3.3 G34M mutation and do not express OLIG2. The vast majority of tumors in our DIPG TMA are positive for OLIG2, consistent with the previous reports. 17 Ligon et al 18 proposed that OLIG2 is required for glioma formation. The proposed role of OLIG2 in glioma formation and its expression in a large percentage of DIPGs make it an attractive target for the treatment of DIPGs.
Nestin is a type VI intermediate filament protein expressed during neural embryogenesis, and it has been shown to be expressed in a variety of brain tumors, including a high percentage of gliomas. 19 Nestin expression has been associated with poor prognosis in gliomas and ependymomas. 19, 20 An increase in Nestin-positive cells in the ventral pons that occurs as part of human development correlates temporally with the age at which most DIPGs occur. 11 On the basis of this temporal correlation, it has been proposed that DIPGs originate from a Nestinpositive population of neural stem cells in the pons. In our study, 21% of DIPGs expressed Nestin, arguing that a Nestin-positive cell population could give rise to DIPGs in a subset of cases. In addition, Park et al 21 suggested that Nestin is important for the survival and self-renewal of neural stem cells. These findings suggest that Nestin could be a potential target for the treatment of DIPGs.
Twenty-five percent of DIPGs expressed BMI1, a polycomb protein that regulates gene expression by modifying chromatin organization. It is expressed in glioblastomas, wherein it is proposed to play a role in maintaining cancer-initiating stem cells. 22 SOX2, OCT4, and Nanog, which are stem cell regulatory genes, have been shown to be expressed in 95% of adult gliomas in a previous study. 10 In this series, higher levels of SOX2 and Nanog were associated with higher tumor grade. The majority of the samples in our TMA were high-grade tumors (grades III and IV). Although most cases were positive for SOX2, all the cases were negative for Nanog. The difference in Nanog expression between adult gliomas and the pediatric brainstem gliomas in our study is an interesting finding that highlights potentially different etiologies for adult and pediatric gliomas. In a study by the Children's Cancer Group, 41 of 115 (B35%) malignant gliomas showed overexpression of p53. 1 Overexpression of p53 protein was associated with poor prognosis as measured by the rate of progressionfree survival at 5 years. In the study by Grill et al, 8 40% of DIPGs showed mutations in p53 when analyzed by a mass spectrometric method of allele detection. In addition, in the study by Louis et al, 23 4 of 7 brainstem gliomas demonstrated loss of portions of chromosome 17p or mutations in p53. Oka et al 24 showed that 80% of DIPG cases were positive for p53 by IHC. In agreement with these results, 83% of cases in our study showed accumulation of p53 protein to a variable degree, with expression ranging from <5% in 5 cases to close to 100% in case #7. These data suggest that p53 dysregulation plays an important role in the majority of cases of DIGPs. Mutations in b-catenin, associated with alteration of Wnt signaling, have been associated with a variety of cancers. In our study, analysis of b-catenin expression in DIPG showed only submembranous/cytoplasmic staining. Nuclear localization of b-catenin, associated with the mutated form of the protein, was not observed.
A genome-wide mutational analysis of glioblastomas identified mutations in IDH1 in a small subset of tumors, which subsequently was found to be present in >70% of diffuse gliomas of all grades and secondary glioblastomas in adults. 25 The presence of mutations in the IDH1 gene correlated with a better outcome. All DIPG cases examined in our series were negative for IDH1 staining with an antibody specific for the mutant form. Although EGFR staining has been reported in pediatric gliomas, EGFR amplification, which is a common finding in adult high-grade astrocytomas, is a rare event in this group. 26 In our TMA, 16/24 (66%) cases were positive for EGFR expression. This is in agreement with the study by Li et al, 27 in which 6/11 (54%) DIPGs cases showed expression of EGFR, suggesting that this could be a potential therapeutic target in a large percentage of cases. To this date, there is no prognostic implication associated with EGFR expression in DIPGs.
In summary, our study shows that DIPGs are heterogenous histologically and in their protein expression and differ from adult high-grade gliomas. Our data also demonstrate that the majority of diffuse intrinsic pontine gliomas are high-grade gliomas that express SOX2, a transcription factor active during embryogenesis, and OLIG2, a regulator of progenitor cell fate, supporting the hypothesis that DIPG is a disorder of development.
Our results also suggest that dysregulation of EGFR and p53 may play an important role in the development of DIPGs. The majority of DIPGs expressed stem cell markers such as SOX2 and OLIG2, and a subset expressed Nestin, consistent with a role for tumor stem cells in the origin and maintenance of these tumors.
Targeted therapies against these proteins may prove beneficial in the treatment of DIPGs in the future.
